论文部分内容阅读
目的:探讨脂蛋白相关磷脂酶A2(lipoprotein associated phospholipase A2,Lp-PLA2)与急性冠状动脉(冠脉)综合征(ACS)的相关性。方法:入选286例因胸痛行冠脉造影患者,其中有165例为ACS(ACS组),73例为稳定型心绞痛(稳定型心绞痛组);48例冠脉造影正常的非冠心病者为对照组,检测各组血浆Lp-PLA2及高敏C反应蛋白(hs-CRP)水平。结果:Lp-PLA2水平在ACS组、稳定型心绞痛组及对照组的水平分别为(115.01±80.74)ng/ml、(90.82±61.58)ng/ml及(82.53±30.89)ng/ml,其中ACS组高于稳定型心绞痛组与对照组(P<0.05)。Hs-CRP水平在ACS组明显高于稳定型心绞痛组及对照组,Lp-PLA2及hs-CRP水平之间无明显相关性。ACS患者血浆Lp-PLA2水平多支冠脉病变组高于单支冠脉病变组(P<0.01),双支冠脉病变组高于单支冠脉病变组(P<0.05)。结论:Lp-PLA2血浆水平可用于间接评估粥样斑块的稳定性及冠脉病变范围。
Objective: To investigate the relationship between lipoprotein associated phospholipase A2 (Lp-PLA2) and acute coronary syndrome (ACS). Methods: A total of 286 patients undergoing coronary angiography with chest pain were enrolled. Among them, 165 patients were ACS (ACS group) and 73 patients with stable angina (stable angina pectoris group); 48 patients with coronary artery disease Group. Plasma Lp-PLA2 and high-sensitivity C-reactive protein (hs-CRP) levels in each group were detected. Results: The levels of Lp-PLA2 were (115.01 ± 80.74) ng / ml, (90.82 ± 61.58) ng / ml and (82.53 ± 30.89) ng / ml respectively in ACS group, stable angina pectoris group and control group, Group was higher than that of stable angina pectoris group and control group (P <0.05). Hs-CRP levels in ACS group was significantly higher than those in stable angina group and control group, Lp-PLA2 and hs-CRP levels had no significant correlation. The level of plasma Lp-PLA2 in patients with ACS was significantly higher than that in patients with single coronary artery disease (P <0.01). The patients with coronary artery disease in two groups were higher than those with coronary artery disease (P <0.05). Conclusion: Lp-PLA2 plasma levels can be used to indirectly assess the stability of atherosclerotic plaques and the extent of coronary lesions.